Incidensen af erklæret svær blødning var 2, 1% (fondaparinux) versus 4, 1% (enoxaparin) til og med ge
4.1% (enoxaparin) up to and including Day 9 in the Phase III UA/ NSTEMI study, and the incidence of adjudicated severe hemorrhage by modified TIMI criteria was 1.1% (fondaparinux) vs.